ZAS Corporation’s Dermatology Division recently organized a Continuing Medical Education (CME) program at BIDSA, focusing on “The Role of Adalimumab in Psoriasis Management.” The session brought together leading dermatology experts to discuss updated clinical guidelines, recent research findings, and practical experiences in using adalimumab to manage moderate to severe psoriasis. Participants engaged in an interactive exchange of ideas, exploring ways to optimize treatment outcomes and enhance patient quality of life. This initiative reflects ZAS Corporation’s ongoing commitment to advancing evidence-based care and fostering professional development in dermatology.